Genome sequencing co Ultima Genomics raises $600m
Genome sequencing organization Ultima Genomics has come out of stealth and introduced $600 million in funding. Founded in 2016 by its Israeli CEO Gilad Almogy, the organization has 350 personnel like 50 in Israel at progress facilities in Rehovot and Hod Hasharon, and remarkably has managed to prevent any leaks of information and facts from its staff, traders and growth facilities.

The organization has now discovered that it has designed a sequencing equipment, which it promises, backed up by investigation established to be posted in foremost scientific periodicals, will allow genome sequencing for $100, as opposed with the $500-600 it prices using its rival Illumina (Nasdaq: ILMN). In addition, Ultima Genomics statements that its genomic sequencing is more quickly and further – in other text, it delivers far more facts about the genome, far more speedily.

The benefits of these enhancements, which are permitted as a result of patents that the enterprise has not yet unveiled, are primarily in two instructions. Via this technology, the business estimates and hopes, it will be attainable to obtain genome sequencing even down to single cells, and thus diagnose sicknesses even earlier than at existing, mainly most cancers. In addition, sequencing that is more cost-effective, a lot quicker and richer in information, will enable significantly a lot quicker development in jobs that compare the genetics of the true morbidity of significant numbers of folks, in purchase to map the genes included in various diseases.

Sources at Ultima Genomics say that the rationale for the secrecy above the years was the motivation to access the level where the organization could prove its item, prior to generating any announcements. The firm also most popular not to stir up its rivals, primarily Illumina.

Ultima Genomics CEO and founder Gilad Almogy is a graduate of the IDF’s Talpiot science and leadership application. Almogy is nowadays resident in the US. He was a senior vice president at Used Supplies before founding photo voltaic electricity company Cogenra Solar in 2009, which was acquired by SunPower in 2015. In late 2016, Almogy started Ultima.

Almogy claimed, “DNA is nature’s storage media and the instruction set for each residing organism, still with present-day systems, we can’t entry that details at the scale desired to certainly recognize sophisticated biology. Our architecture is meant for radical scaling, and the $100 genome is simply the initially illustration of what it can supply. We are dedicated to consistently generate down the charge of genomic info right up until it is routinely applied in each and every aspect of the health care procedure.”




Related Articles or blog posts




aMoon closes $660m Israeli well being-tech VC fund







Ultima Genomics CSO Doron Lipson extra, “Experts and clinicians continuously make tradeoffs concerning the breadth, depth, and frequency of genomic information they accumulate. By beating the constraints of standard up coming-technology sequencing systems, scientists can now layout experiments and scientific assays that had been beforehand extremely hard.”

A person of the first investors in Ultima Genomics was Israeli billionaire and Check Position founder Marius Nacht, who is also a graduate of the IDF’s Talpiot software. Nqcht started the aMoon healthtech and everyday living science expense fund, to begin with investing his have belongings in advance of turning out to be an unbiased fund, which in the latest decades elevated a $750 million expansion fund. aMoon has also invested in Ultima Genomics.

Other buyers in Ultima Genomics involve D1 Money, Andreessen Horowitz, Basic Atlantic, Khosla Ventures, Lightspeed, Playground Global, and Founders Fund.

Complete disclosure: Marius Nacht is the previous lifestyle lover of Anat Agmon, element of the managing shareholders in “Globes.” They are involved in a private and financial dispute

Published by Globes, Israel small business information – en.globes.co.il – on June 2, 2022.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2022.